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Our previous studies revealed that insulin stimulates
the tyrosine phosphorylation of caveolin in 3T3L1 adi-
pocytes. To explore the mechanisms involved in this
event, we evaluated the association of the insulin recep-
tor with caveolin. The receptor was detected in a Triton-
insoluble low density fraction, co-sedimenting with
caveolin and flotillin on sucrose density gradients. We
also detected the receptor in caveolin-enriched rosette
structures by immunohistochemical analysis of plasma
membrane sheets from 3T3L1 adipocytes. Insulin stim-
ulated the phosphorylation of caveolin-1 on Tyr14. This
effect of the hormone was not blocked by overexpres-
sion of mutant forms of the Cbl-associated protein that
block the translocation of phospho-Cbl to the caveolin-
enriched, lipid raft microdomains. Moreover, this phos-
phorylation event was also unaffected by inhibitors of
the MAPK and phosphatidylinositol 3-kinase pathways.
Although previous studies demonstrated that the Src
family kinase Fyn was highly enriched in caveolae, an
inhibitor of this kinase had no effect on insulin-stimu-
lated caveolin phosphorylation. Interestingly, overex-
pression of a mutant form of caveolin that failed to in-
teract with the insulin receptor did not undergo
phosphorylation. Taken together, these data indicate
that the insulin receptor directly catalyzes the tyrosine
phosphorylation of caveolin.
The insulin receptor is a tyrosine kinase that undergoes
ligand-stimulated autophosphorylation and activation of its
intrinsic substrate kinase activity (1). Once activated, the re-
ceptor phosphorylates intracellular substrates on tyrosine, in-
cluding members of the insulin receptor substrate family
(IRS1/2/3/4),1 Shc, SIRP, Gab-1, Cbl, and APS (2–4). Tyrosine
phosphorylation of these proteins creates recognition sites for
effector molecules containing Src homology 2 (SH2) and phos-
photyrosine binding domains. These include the small adapter
proteins Grb2, CrkII, and Nck, the SHP2 protein-tyrosine
phosphatase and the regulatory subunit of the type 1A phos-
phatidylinositol 3-kinase (PI3K) (4). The insulin receptor-de-
pendent tyrosine phosphorylation of both IRS1 and IRS2 are
critical in maintaining proper glucose homeostasis through its
interaction with the PI3K (5–9). This interaction appears to
serve a dual function by stimulating PI3K activity and target-
ing the enzyme to a critical intracellular site (10). Studies using
various pharmacological inhibitors, microinjection of blocking
antibodies, expression of dominant-interfering, and constitu-
tively active mutants have consistently demonstrated a neces-
sary role for PI3K activity in most of the metabolic effects of
insulin (11, 12). Furthermore, inhibition of PI(3,4,5)P3 forma-
tion (a product of PI3K) by expression of the 3-phosphatase
phosphatase and tensin homolog or the 5-phosphatase SH2
inositol 5-phosphatase prevents insulin-stimulated glucose up-
take and Glut4 translocation (13, 14).
Despite the general agreement that PI3K activity is neces-
sary for insulin action, several studies have demonstrated the
requirement for additional signals (15–18). For example, acti-
vation of PI3K by platelet-derived growth factor and interleu-
kin-4 or through engagement of integrin receptors does not
induce Glut4 translocation (15, 16, 19). Furthermore, two nat-
urally occurring insulin receptor mutations were unable to
induce Glut4 translocation and glucose uptake, yet were fully
capable of activating PI3K (20). Additionally, a cell-permeable
analog of PI(3,4,5)P3 had no effect on glucose uptake (17).
These data suggest that, although the PI3K pathway is neces-
sary, there is at least one additional pathway required.
Recent data suggest that the second requisite pathway might
involve tyrosine phosphorylation events that are restricted to
subdomains of the plasma membrane. The insulin-stimulated
tyrosine phosphorylation of Cbl results in its appearance in
caveolin-enriched, lipid raft subdomains of the plasma mem-
brane in 3T3L1 adipocytes (21–23). Cbl is recruited to the
insulin receptor by the adapter protein APS, which is necessary
for its insulin-stimulated tyrosine phosphorylation (24). The
Cbl and APS proteins form a trimeric complex with the adapter
protein CAP, a member of the SoHo family of proteins that
contains a flotillin-binding SoHo domain in it amino terminus,
and three adjacent SH3 domains in its carboxyl terminus (22,
23, 25). Once phosphorylated, the CblCAP complex is recruited
to lipid rafts through the interaction of CAP with flotillin.
Expression of dominant-interfering CAP mutants that lack
either the SH3 or SoHo domains prevented the localization of
this complex to plasma membrane microdomains and inhibited
the stimulation of glucose uptake and GLUT4 translocation by
insulin (25).
Following insulin-stimulated tyrosine phosphorylation, Cbl
recruits the SH2-containing adapter protein CrkII to lipid
rafts; along with the guanine nucleotide exchange factor C3G
(21, 23, 26). Upon its translocation, C3G activates TC10, a
* This work was supported by National Institutes of Health Grants
DK60591 (to A. R. S.) and DK59291 and DK33823 (to J. E. P.). The
costs of publication of this article were defrayed in part by the payment
of page charges. This article must therefore be hereby marked “adver-
tisement” in accordance with 18 U.S.C. Section 1734 solely to indicate
this fact.
¶ To whom correspondence should be addressed: Depts. of Medicine
and Physiology, Life Sciences Institute, University of Michigan School
of Medicine, Ann Arbor, MI 48109-0650. Tel.: 734-615-9787; Fax: 734-
936-2888; E-mail: saltiel@umich.edu.
1 The abbreviations used are: IRS1–4, insulin receptor substrates
1–4; SH2, Src homology 2 domain; PI3K, phosphatidylinositol 3-kinase;
CAP, Cbl-associated protein; MES, 4-morpholineethanesulfonic acid;
MAPK, mitogen-activated protein kinase; MEK, MAPK/extracellular
signal-regulated kinase kinase; PI(3,4,5)P3, phosphatidylinositol 3,4,5
Tris phosphate; Glut4, glucose transporter 4.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 277, No. 33, Issue of August 16, pp. 30153–30158, 2002
© 2002 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 30153
member of the Rho family protein of small GTP binding pro-
teins expressed in muscle and adipose tissue (27). TC10 is
specifically activated by insulin in 3T3L1 adipocytes in a CAP-
dependent but PI3K-independent manner (26). Although the
physiologically relevant effectors that interact with TC10 are
unknown, disruption of its activation blocks insulin-stimulated
glucose transport and Glut4 translocation. Moreover, mistar-
geting of TC10 to a non-lipid raft domain by production of a
TC10/K-Ras chimera or by disruption of lipid raft microdo-
mains via expression of a dominant-interfering mutant form of
caveolin-3 also completely prevented the activation of TC10 by
insulin (28).
Although the precise function of lipid raft subdomains in
assembling this signaling complex remains uncertain, resident
structural proteins may play an important role. One such pro-
tein is caveolin-1, which is highly expressed in mature adipo-
cytes (29) and is known to undergo tyrosine phosphorylation in
various cells (30–33). Caveolin is tyrosine-phosphorylated in
response to insulin in 3T3L1 adipocytes but not fibroblasts (30).
Although this phosphorylation event correlates well with insu-
lin responsiveness, the significance of caveolin phosphorylation
remains uncertain. Moreover, it is unclear whether this phos-
phorylation event is a direct result of the tyrosine kinase ac-
tivity of the insulin receptor or perhaps catalyzed by the Src
family kinase Fyn, which is also highly enriched in caveolae of
adipocytes (30). We demonstrate here that insulin receptor
physically associates with caveolin in 3T3L1 adipocytes and,
further, that caveolin is a direct substrate of the insulin
receptor.
EXPERIMENTAL PROCEDURES
Materials—The anti-caveolin-2, insulin receptor  subunit and Myc
antibodies were purchased from Santa Cruz Biotechnology. The FLAG
(M2) antibody was obtained from Stratagene. The anti-phosphotyrosine
antibody (4G10) was from Upstate Biotechnology Inc. The phospho-
p42/44 MAPK and phospho-Akt (4E2) antibodies were from Cell Sig-
naling Technology. The anti-insulin receptor  subunit antibodies for
immunofluorescence as well as the anti-caveolin-1, paxillin, and phos-
pho-caveolin (Tyr14) antibodies were from Transduction Laboratories.
We used horseradish peroxidase-linked secondary antibodies (Bio-Rad)
and enhanced chemiluminescence (Amersham Biosciences) for immu-
noblot detection. The Alexa Fluor secondary antibodies were from Mo-
lecular Probes. PD98059 and PP2 were from Calbiochem. Wortmannin
was from Sigma Chemical Co. Octylthioglucoside was purchased from
Roche Molecular Biochemicals.
Plasmids and Mutagenesis—The cDNA of mouse caveolin-1 was am-
plified by PCR from a 3T3L1 adipocyte cDNA library as the template.
The 5 primer was designed to have a BamHI restriction site followed by
the amino acids 1–27. The 3 primer was designed to have an EcoRI
restriction site followed by the amino acids 515–537 according to Gen-
BankTM U07645. These PCR products were cloned into pKMyc vector.
FLAG-tagged CAP and CAP mutants were made as described previ-
ously (23, 25). All mutated forms of caveolin-1 were generated using the
Stratagene QuikChange mutagenesis kit, according to the manufactur-
er’s protocol. The mutations were confirmed by automated DNA
sequencing.
Cell Culture and Transfection—3T3L1 fibroblasts were maintained
in Dulbecco’s modified Eagle’s medium supplemented with 10% calf
serum, 100 units/ml penicillin G sodium, and 100 g/ml streptomycin
sulfate. Differentiation to adipocytes was induced, and cells were cul-
tured in Dulbecco’s modified Eagle’s medium containing 10% fetal bo-
vine serum. 3T3L1 adipocytes were transfected by electroporation as
described previously (23, 25).
Immunoprecipitation and Immunoblotting—Cells were washed twice
with ice-cold phosphate-buffered saline and were lysed for 30 min at
4 °C with buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1%
Triton X-100, 1.0 mM EDTA, 1.0 mM sodium pyrophosphate, 1.0 mM
sodium orthovanadate, 10 mM NaF, and protease inhibitors (1 tablet
per 10 ml of buffer) (Roche Diagnostics). The clarified lysates were
incubated with the indicated antibodies for 1 h at 4 °C. The immune
complexes were precipitated with protein A/G-agarose (Santa Cruz
Biotechnology) for 1 h at 4 °C and were washed extensively with lysis
buffer before solubilization in SDS sample buffer. Bound proteins were
resolved by SDS-PAGE and transferred to nitrocellulose membranes.
Individual proteins were detected with the specific antibodies and vi-
sualized by blotting with horseradish peroxidase-conjugated secondary
antibodies.
Fractionation of Triton-insoluble Pellet—The Triton-insoluble pellet
fraction was generated as described previously (21, 30). Briefly, cells
were washed with ice-cold phosphate-buffered saline and lysed in MBS
buffer (25 mM MES, pH 6.0; 1% Triton X-100, 150 mM NaCl, 10 mM NaF,
10 mM Na-pyrophosphate, 1 mM EDTA, 1 mM PMSF, 10 g/ml aproti-
nin, 1 mM benzamidine) containing protease inhibitors and sodium
orthovanadate. Lysed cells were kept at 4 °C to prevent degradation of
caveolar complexes. The Triton-insoluble pellet fraction was solubilized
in SOL buffer (25 mM Tris, pH 8.0; 1% Triton X-100, 150 mM NaCl, 10
mM NaF, 10 mM Na-pyrophosphate, 1 mM EDTA, 60 mM octylthioglu-
coside, 1 mM PMSF, 10 g/ml aprotinin, 1 mM benzamidine) containing
60 mM octylthioglucoside.
Fluorescence Microscopy—3T3L1 adipocytes were grown on glass
cover slips in six-well dishes. Cells were fixed with 10% formalin for 10
min, permeabilized with 0.5% Triton X-100 for 5 min, and blocked with
3% bovine serum albumin and 1% ovalbumin for 1 h. Primary and Alexa
Fluor secondary antibodies were used at 2 g/l in blocking solution,
and samples were mounted on glass slides with Vectashield (Vector
Laboratories). Cells were imaged using confocal fluorescence micros-
copy. Fluorescent intensities were quantitated using the Olympus Fluo-
view software. Images were then imported into Adobe Photoshop
(Adobe Systems, Inc.) for processing.
Sucrose Gradient Centrifugation—Isolation of caveolae-enriched
fractions was performed as previously described with minor modifica-
tions (30). Briefly, differentiated 3T3L1 adipocytes were washed with
ice-cold phosphate-buffered saline and rapidly scraped in 0.5 M sodium
carbonate buffer (pH 11) and homogenized with 10 strokes in a Dounce
glass homogenizer. The homogenates were then sonicated three times
for 20 s at the setting of 4.5 in a Fisher 550 sonic dismembrator. The
samples were combined with 60% (w/v) sucrose in 25 mM MES, pH 6.5,
150 mM NaCl and well mixed to achieve a final sucrose concentration of
40%. The homogenates were overlaid with 4 ml of 35% (w/v) sucrose and
then with 3 ml of 5% (w/v) sucrose in 25 mM MES, pH 6.5, 150 mM NaCl.
The samples were spun at 39,000 rpm in an SW 41 rotor at 4 °C for 19 h,
and 1-ml fractions were collected for immunoblotting.
RESULTS
The Insulin Receptor Is Localized in Rosette Structures in
3T3L1 Adipocytes—To determine whether the tyrosine phos-
phorylation of caveolin might be catalyzed directly by the in-
sulin receptor, we explored the localization of the receptor in
membranes of 3T3L1 adipocytes. Cells were lysed in buffer
containing Triton X-100 and purified on sucrose density gradi-
ents (Fig. 1). As previously observed, under these gradient
conditions caveolin and flotillin migrate in the low density
region (Fig. 1A, fractions 3 and 4) of the sucrose gradient
consistent with lipid raft enrichment. The insulin receptor was
found in the more dense regions of the gradient but also co-
migrated with caveolin-1 and flotillin in the low density frac-
tions. As expected, insulin stimulation resulted in the recruit-
ment of C3G to the low density fractions, whereas the p85
regulatory subunit of PI3K was not detected in these fractions,
irrespective of insulin treatment (Fig. 1B). To confirm that a
population of the insulin receptor is co-localized with caveolin,
plasma membrane sheets were prepared from 3T3-L1 adipo-
cytes (28), and stained with antibodies to caveolin-2 or the
insulin receptor beta subunit. As is seen in Fig. 1C, both caveo-
lin and insulin receptor reside in characteristic large clusters of
caveolae that take on a rosette or ring-like appearance in
adipocytes (28). Both caveolin-1 and -2 are localized in these
structures (data not shown).
Insulin Stimulates the Phosphorylation of Caveolin-1 on
Tyr14—Previous studies suggested that the insulin-stimulated
tyrosine phosphorylation of caveolin might be secondary to the
phosphorylation of Cbl and its subsequent translocation to lipid
raft microdomains (23). This translocation depends on the
binding of Cbl to the adapter protein CAP, and the subsequent
interaction of the second protein with the raft protein flotillin
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(23). The insulin-stimulated translocation of phospho-Cbl to
these microdomains is blocked by overexpression of deletion
mutants of CAP lacking the Cbl-interacting SH3 domains
(CAPSH3) or flotillin-binding SoHo domain (CAPSoHo) (23,
25). To determine whether CblCAP signaling is involved in
caveolin-1 phosphorylation, FLAG-tagged CAP, CAPSoHo,
and CAPSH3 were expressed in 3T3-L1 adipocytes. The phos-
phorylation of caveolin-1 on Tyr14 in response to insulin was
evaluated using a phosphospecific antibody (Fig. 2). Insulin
stimulated the tyrosine phosphorylation of caveolin-1, using
the phosphospecific antibodies to the sequences surrounding
Tyr14 (Fig. 2D, lanes 1 and 2). Identical results were generated
using anti-phosphotyrosine antibodies (data not shown). As
previously reported (25), expression of CAP, CAPSoHo, or
CAPSH3 did not effect the stimulation of Akt or MAPK phos-
phorylation in response to insulin. Similarly, expression of
CAP, CAPSoHo, or CAPSH3 had no effect on insulin-stim-
ulated caveolin phosphorylation (Fig. 2D, lanes 3–8), indicating
that the CblCAP pathway is not required for phosphorylation
of caveolin-1. As controls, the relative expression levels of CAP,
CAPSoHo, CAPSH3, and endogenous caveolin are shown.
Because the tyrosine phosphorylation of caveolin appears to be
independent of the CAP/Cbl pathway, we sought to examine the
potential role of the PI3K and MAPK pathways in this event (Fig.
3). 3T3L1 adipocytes were pretreated with PD98059 (Fig. 3, lanes
3 and 4), a pharmacological inhibitor of MEK that has been
shown to block the MAPK pathway (34) as well as wortmannin
(Fig. 3, lanes 5 and 6), an inhibitor of PI3K (35), followed by
exposure to insulin. As expected, neither inhibitor blocked IRS-1
or insulin receptor tyrosine phosphorylation (Fig. 3A), although
wortmannin blocked the phosphorylation of Akt (Fig. 3B) and
PD98059 blocked the phosphorylation of MAPK (Fig. 3C). More-
over, the tyrosine phosphorylation of caveolin was unaffected by
both inhibitors (Fig. 3D), indicating that this phosphorylation
event is independent of the MAPK and PI3K pathways.
Caveolin-1 was first identified as a tyrosine-phosphorylated
protein in v-Src-transformed cells (36) and is known to be
constitutively tyrosine-phosphorylated in Src- and Abl-trans-
formed cells (33). Moreover, previous studies (30) revealed that
the Src family kinase Fyn is abundant in Triton-insoluble low
density complexes derived from 3T3L1 adipocytes. To examine
if insulin-stimulated caveolin phosphorylation is a consequence
of Fyn activity, 3T3L1 adipocytes were pretreated with the Src
family kinase inhibitor PP2 prior to insulin treatment, and
caveolin phosphorylation was evaluated (Fig. 4). This com-
pound is known to specifically inhibit Src family tyrosine ki-
nases in cells, including the kinase Fyn (37, 38). The compound
FIG. 1. Colocalization of insulin receptor and caveolin in
3T3L1 adipocyte plasma membranes. A, fully differentiated 3T3L1
adipocytes were non-detergent-homogenized, sonicated, and subjected
to sucrose density gradient fractionation as described under “Experi-
mental Procedures.” The gradient fractions from low (1) to higher (12)
density were subjected to SDS-PAGE and immunoblotted with caveolin,
flotillin, and insulin receptor  subunit antibodies. B, adipocytes were
stimulated with (Insulin) and without (Basal) 100 nM insulin for 5 min
prior to sucrose gradient centrifugation. The fractions were immuno-
blotted with C3G and PI3K p85 regulatory subunit antibodies. C,
plasma membrane sheets were prepared from 3T3L1 adipocytes, as
detailed in “Experimental Procedures.” Sheets were probed with anti-
bodies to caveolin or the  subunit of the insulin receptor, as indicated.
These are representative experiments that were repeated five times.
FIG. 2. Insulin-stimulated tyrosine phosphorylation of caveo-
lin-1 is independent of the CblCAP pathway. Fully differentiated
3T3L1 adipocytes were electroporated with 200 g of vector control
(VA), FLAG-tagged CAP (CAP), CAPSoHo (SoHo), or CAPSH3
(SH3) cDNA. Cells were placed in serum-free medium and starved for
3 h before treatment with 100 nM insulin for 5 min. Cell lysates were
separated by SDS-PAGE, transferred to nitrocellulose, and blotted with
FLAG (A), phospho-AKT (B), phospho-ERK (C), phospho-cave-
olin(Tyr14) (D) and caveolin-1 antibodies (E). Shown is a representative
experiment that was repeated three times.
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had no effect on insulin receptor or IRS-1 tyrosine phosphoryl-
ation (Fig. 4A) or on the activation of Akt (Fig. 4B) or MAPK
(Fig. 4C) in response to insulin. Furthermore, PP2 pretreat-
ment failed to inhibit basal and insulin-stimulated phosphoryl-
ation of caveolin-1 (Fig. 4D). In contrast, PP2 pretreatment
completely blocked the constitutive phosphorylation of FAK, a
known substrate of Src family kinases such as Fyn (Fig. 4E),
although the dephosphorylation of the protein produced by
insulin (39) was not affected. Additionally, addition of PP2
blocked the constitutive tyrosine phosphorylation of paxillin
and Pyk2 in these cells (data not shown).
Previous reports have demonstrated that palmitoylation-de-
ficient caveolin-1 cannot be phosphorylated on Tyr14 by c-Src
(33). Moreover, Cys156 appears to be required for the interac-
tion of caveolin-1 with Src family kinases, because substitution
of Cys156 with Ser inhibited the c-Src-catalyzed phosphoryla-
tion of the protein (33). To further explore the role of Fyn in
insulin-induced phosphorylation of caveolin-1, we expressed
mutant forms of caveolin-1 in 3T3L1 adipocytes and analyzed
tyrosine phosphorylation (Fig. 5). Cells were transfected by
electroporation (23, 25) with vector alone (VA, lanes 1 and 2),
wild type caveolin-1 (WT, lanes 3 and 4), a caveolin mutant in
which Tyr14 was mutated to phenylalanine (Y14F, lanes 5 and
6), and a caveolin-1 mutant in which Cys156 was mutated to
serine (C156S, lanes 7 and 8). All of these constructs encoded
proteins that were myc-tagged and were expressed at levels
roughly equal to those of the endogenous caveolin, as detected
by blotting with anti-caveolin antibodies (Fig. 5E). Expression
of wild type caveolin, Cav(Y14F) or Cav(C156S) had no effect on
the stimulation of IR, IRS-1, Akt, and ERK phosphorylation in
response to insulin (Fig. 5, A–C). Furthermore, the ectopic
expression of these proteins did not inhibit the tyrosine phos-
phorylation of endogenous caveolin-1 (Fig. 5D). Myc-tagged
wild type caveolin was phosphorylated in response to insulin as
was Cav(C156S). In contrast, Cav(Y14F) did not undergo phos-
phorylation in response to insulin. Probing this blot with anti-
phosphotyrosine antibodies also revealed no phosphorylation
(data not shown), indicating that insulin stimulates the phos-
phorylation of caveolin primarily on Tyr14. Interestingly, ex-
pression of the Y14F mutant of caveolin-1 did not produce a
dominant-interfering phenotype regarding phosphorylation of
the endogenous protein, suggesting that significant overex-
pression of the protein will be required to observe this effect.
The data described above suggest that caveolin phosphoryl-
ation is likely to be catalyzed directly by the insulin receptor.
To explore this possibility in more detail, we sought to evaluate
FIG. 3. Insulin-stimulated tyrosine phosphorylation of caveo-
lin-1 is PI3K- and MAPK-independent. 3T3L1 adipocytes were
placed in serum-free medium for 3 h and incubated for 30 min with 100
nM wortmannin or 10 M PD98059 prior to 100 nM insulin treatment for
5 min. Cell lysates were separated by SDS-PAGE, transferred to nitro-
cellulose, and blotted with 4G10 (A), phospho-AKT (B), phospho-ERK
(C), and phospho-caveolin(Tyr14) antibodies (D). Shown is a represent-
ative experiment that was repeated three times.
FIG. 4. Insulin-stimulated tyrosine phosphorylation of caveo-
lin-1 is PP2-insensitive. Cells were placed in serum-free medium for
3 h and incubated for 20 min with 1 M vehicle (Me2SO (DMSO)) or PP2
prior to insulin stimulation at 100 nM for 5 min. Cell lysates were
separated by SDS-PAGE, transferred to nitrocellulose, and blotted with
4G10 (A), phospho-AKT (B), phospho-ERK (C), phospho-caveolin(Tyr14)
(D), and phospho-FAK antibodies (E). Shown is a representative exper-
iment that was repeated three times.
FIG. 5. Palmitoylation of caveolin-1 at Cys156 is not required
for insulin-stimulated phosphorylation. Fully differentiated
3T3L1 adipocytes were electroporated with 200 g of vector control,
Myc-tagged caveolin-1 wild type (WT), caveolin-1 Y14F mutant (Y14F),
or caveolin-1 C156S mutant (C156S). Thirty-six hours after electropo-
ration, cells were placed in serum-free medium for 3 h before treatment
with 100 nM insulin for 5 min. Cell lysates were separated by SDS-
PAGE, transferred to nitrocellulose, and blotted with 4G10 (A), phos-
pho-AKT (B), phospho-ERK (C), phospho-caveolin (Tyr14) (D), and myc
antibodies (E). Anti-phospho-caveolin(Tyr14) antibodies recognized both
expressed caveolin-1 and endogenous-caveolin-1  forms upon phospho-
rylation. Anti-myc antibodies recognized only expressed caveolin-1.
Shown is a representative experiment that was repeated three times.
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a domain on caveolin that is thought to interact with proteins
in caveolae. Caveolin contains a short stretch of amino acids in
its amino terminus around residues 80–100 that may mediate
these interactions (40), including those with the insulin recep-
tor (41). To determine whether direct interactions between
caveolin-1 and the insulin receptor are required for insulin-
stimulated phosphorylation of caveolin, a mutant form of the
protein was constructed in which Phe92 and Val94 were mu-
tated to alanine (Cav(FAVA)). This construct was transfected
into 3T3L1 adipocytes, along with wild type caveolin-1 (Fig. 6).
Although the expression levels of Cav(FAVA) were signifi-
cantly lower than that observed for the wild type form of the
protein, it was possible to detect the protein by blotting with
anti-myc or anti-caveolin antibodies (Fig. 6C). Cav(FAVA) was
detected at the plasma membrane and localized in Triton-
insoluble fractions, typical of wild type caveolin. Moreover,
overexpression of this mutant had no effect on the distribution
of the insulin receptor in these low density fractions (data not
shown). Expression of wild type caveolin or Cav(FAVA) had no
effect on insulin receptor autophosphorylation (Fig. 6A) or on
levels of endogenous caveolin (Fig. 6C). However, the tyrosine
phosphorylation of endogenous caveolin-1 was significantly in-
hibited by expression of Cav(FAVA) (Fig. 6B). Furthermore,
expressed Cav(FAVA) was not phosphorylated in response to
insulin, whereas wild type caveolin did undergo tyrosine
phosphorylation.
DISCUSSION
Recent evidence suggests that signaling molecules and path-
ways are restricted to discrete compartments in cells by specific
protein interactions. Lipid raft subdomains have been impli-
cated as sites for signal initiation in numerous cell types (42).
In adipocytes and muscle cells, much attention has focused on
the caveolae, a subset of lipid raft microdomains. These small
invaginations of the plasma membrane are often enriched in
signaling molecules, glycolipids, and cholesterol and have been
proposed to act as signaling organelles (43). Based on the
identification of a signaling complex in caveolae involving APS,
Cbl, CAP, and TC10, we have hypothesized that the segrega-
tion to these domains might provide a potential explanation for
the specificity of signal transduction in insulin action (2). Dis-
ruption of caveolae with cholesterol-extracting drugs, such as
-cyclodextrin, or expression of a dominant negative form of
caveolin-3 (28) blocked specifically the initiation of this path-
way and prevented the stimulation of glucose transport and
Glut4 translocation in response to insulin (44).
The caveolin family of proteins appears to play a particularly
important role in the formation of caveolae and possibly in
signaling activities that occur in these microdomains. Disrup-
tion of the gene encoding caveolin-1 results in a failure of lung
epithelial cells and adipocytes to form caveolae (45, 46), al-
though the impact of this manipulation on signal transduction
has not been studied. Numerous studies have demonstrated
that caveolin interacts with a number of signaling molecules
that are thought to be enriched in caveolae, including certain
small and heterotrimeric G proteins (40, 47), endothelial nitric-
oxide synthase (48, 49), and a subset of tyrosine kinase recep-
tors (50), including the insulin receptor (41, 51). Caveolin is
also known to undergo tyrosine phosphorylation in some cases
(30–33). We first demonstrated that insulin could specifically
stimulate the phosphorylation of caveolin in 3T3L1 adipocytes
(31). This effect of the hormone was rapid, dose-dependent, and
specific for insulin. Interestingly, the effect was not observed in
3T3L1 pre-adipocytes, which express both caveolin and the
insulin receptor, suggesting that caveolin phosphorylation cor-
relates with metabolic responsiveness to insulin (30).
Although the mechanism involved in the insulin-stimulated
phosphorylation of caveolin has not been established, previous
studies suggested that the Src family kinase Fyn might cata-
lyze this event (30). Fyn is highly expressed n 3T3L1 adipocytes
and co-purifies with caveolin in Triton-insoluble low density
complexes. Moreover, caveolin undergoes hyperphosphoryla-
tion upon overexpression of Fyn in these cells (30). However,
the data presented in this study strongly support a direct
insulin receptor-mediated tyrosine phosphorylation of caveolin
on Tyr14 of the protein. This phosphorylation does not require
the activation of PI3K or MAPK and is independent of the
phosphorylation and translocation of Cbl to the lipid raft mi-
crodomain. Furthermore, this phosphorylation event does not
rely on the activity of the Fyn tyrosine kinase, because inhib-
itors of this enzyme have no inhibitory effect on caveolin phos-
phorylation. Finally, expression in cells of a mutant form of
caveolin that cannot be phosphorylated by Src family kinases
still undergoes insulin-stimulated phosphorylation, whereas
expression of a mutant form of the protein that cannot interact
with the insulin receptor is not phosphorylated in these cells.
Moreover, the insulin receptor is localized to plasma membrane
domains that are highly enriched in caveolin. Taken together,
these observations strongly suggest that caveolin is a direct
substrate of the insulin receptor.
What is the biological significance of increased caveolin ty-
rosine phosphorylation that occurs after insulin stimulation in
adipocytes? Unfortunately, it was not possible to block this
event by overexpression of a phosphorylation-deficient mutant
form of caveolin (Y14F), because we were unable to attain the
expression levels required to block phosphorylation of the en-
dogenous protein. Thus, expression of a dominant negative
form of caveolin in cells metabolically responsive to insulin will
likely require a knock-out/knock-in strategy. Although there
are no data on the functional alterations in caveolin as a
consequence of phosphorylation on Tyr14, it is possible to spec-
ulate about phosphotyrosine-dependent interactions that
might recruit proteins to these domains in an insulin-depend-
ent manner, perhaps via SH2 interactions. In this regard, Grb7
and -14 have been proposed to interact with caveolin in a
tyrosine phosphorylation-dependent manner (33), although we
have been unable to detect insulin-dependent interactions with
these adapter proteins in adipocytes (data not shown). It is also
possible that caveolin might itself regulate the activity of the
insulin receptor, increasing its activity toward other substrates
FIG. 6. Caveolin scaffolding domain is required for insulin-
stimulated phosphorylation. Fully differentiated 3T3-L1 adipocytes
were electroporated with 200 g of Myc-tagged caveolin-1 wild type
(WT) or caveolin-1 F92A/V94A mutant (FAVA). Cells were incubated
with 100 nM insulin for 5 min, 36 h after electroporation. The Triton-
insoluble pellet fraction (see “Experimental Procedures”) were sepa-
rated by SDS-PAGE, transferred to nitrocellulose, and blotted for 4G10
(A), phospho-caveolin(Tyr14) (B) or anti-caveolin-1 antibodies (C).
Shown is a representative experiment that was repeated three times.
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(41). Finally, the possibility remains that the tyrosine phospho-
rylation of caveolin by the insulin receptor is merely a result of
the interaction of these two molecules and, further, that the
binding of caveolin to the receptor helps to recruit the latter
protein to caveolae, where it initiates the CAP/Cbl signaling
pathway. These possibilities will be the subject of future
studies.
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